Collaboration Boehringer Ingelheim Veeva technology Collaboration Boehringer Ingelheim Veeva technology Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
EU approved Jardiance for type 2 diabetes in children EU approved Jardiance for type 2 diabetes in children Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
Interview Dr Mehdi Shahidi Interview Dr Mehdi Shahidi Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
Boehringer Ingelheim Venture Fund invests precision antimicrobials Boehringer Ingelheim Venture Fund invests precision antimicrobials Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials
Supply Chain Scholarship for Cowtribe Supply Chain Scholarship for Cowtribe A supply chain course we sponsored boosted the career of Latifa Saaka
Winners of BVDzero Scholarship Programme Winners of BVDzero Scholarship Programme Boehringer Ingelheim announces winners of BVDzero Scholarship Programme
Zongertinib positive results non-small cell lung cancer Zongertinib positive results non-small cell lung cancer Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Rainbow Pizza Video Rainbow Pizza Video Find out how this rainbow pizza from Taking Cancer on Through Flavour is made
Survodutide Phase III study weight loss Survodutide Phase III study weight loss Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
Boehringer and ZEISS partnership eye diseases Boehringer and ZEISS partnership eye diseases Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
Joint venture to fight Antimicrobial Resistance Joint venture to fight Antimicrobial Resistance Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
Classical Swine Fever live vaccine approved in China Classical Swine Fever live vaccine approved in China Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
InPedILD_trial_enrollment InPedILD_trial_enrollment First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Rare Diseases: Rare but not alone Rare Diseases: Rare but not alone We are committed to listen and learn from patients with rare diseases to deliver breakthrough therapies.
Jean-Michel Boers Appointed to PhRMA Board of Directors Jean-Michel Boers Appointed to PhRMA Board of Directors Jean-Michel Boers Appointed to PhRMA Board of Directors
Advance study vaccinating increased milk production Advance study vaccinating increased milk production [New ADVANCE study shows vaccinating with Bovela® results in increased milk production
FDA-approves-nintedanib-in-SSc-ILD FDA-approves-nintedanib-in-SSc-ILD FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD